3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole
C17H21F2N7O — CID 85468735
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole
3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole (PubChem CID 85468735) has the molecular formula C17H21F2N7O and a molecular weight of 377.40 g/mol. Its IUPAC name is 3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole.
Molecular Properties
| Compound Name | 3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole |
|---|---|
| PubChem CID | 85468735 |
| Molecular Formula | C17H21F2N7O |
| Molecular Weight | 377.40 g/mol |
| Exact Mass | 377.18 |
| IUPAC Name | 3-[[6-tert-butyl-4-(3,3-difluoropyrrolidin-1-yl)pyrazolo[5,4-d]pyrimidin-1-yl]methyl]-4-methyl-1,2,5-oxadiazole |
| SMILES | Cc1nonc1Cn1ncc2c(N3CCC(F)(F)C3)nc(C(C)(C)C)nc21 |
| InChI | InChI=1S/C17H21F2N7O/c1-10-12(24-27-23-10)8-26-14-11(7-20-26)13(21-15(22-14)16(2,3)4)25-6-5-17(18,19)9-25/h7H,5-6,8-9H2,1-4H3 |
| InChIKey | YLOBYAWMYVSJMP-UHFFFAOYSA-N |
| XLogP | 2.71 |
| TPSA | 85.76 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 377.40 |
| LogP ≤ 5 | 2.71 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 85468735 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.